Related Experiment Video
Updated: Nov 14, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antithrombotic treatment in primary percutaneous coronary intervention
Felix Voll1, Constantin Kuna1, Gjin Ndrepepa1
1Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
Insights
Optimal antithrombotic therapy for ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI) requires balancing bleeding and clotting risks. Early antiplatelet and anticoagulation, followed by tailored long-term treatment, improves outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI) face elevated risks of adverse cardiovascular events.
- Guideline-directed antithrombotic therapy effectively reduces these risks, yet improvements are still needed.
Purpose of the Study:
- To review current data on antithrombotic therapy in STEMI patients undergoing pPCI.
- To discuss strategies for optimizing antithrombotic treatment in this high-risk population.
Main Methods:
- Literature review of current data on antithrombotic therapy in STEMI patients undergoing pPCI.
Main Results:
- Early administration of antiplatelet agents and anticoagulation is crucial for achieving adequate antithrombotic effect during pPCI.
- Long-term antithrombotic strategies should be individualized based on patient-specific thrombotic and bleeding risks.
Conclusions:
- Antithrombotic therapy must address both short-term and long-term risks of thrombosis and bleeding in STEMI patients post-pPCI.
- Tailoring therapy ensures adequate secondary ischemic prevention while minimizing excess bleeding complications.
Introduction:
Despite a timely mechanical reperfusion with primary percutaneous coronary intervention (pPCI) patients presenting with ST-elevation myocardial infarction (STEMI) display an increased risk of adverse cardiovascular events. Several studies have demonstrated that guideline-directed antithrombotic therapy is effective to reduce this risk. However, there is still much to be accomplished to improve antithrombotic therapies in this clinical setting.
Areas Covered:
This paper reviews current data on antithrombotic therapy in STEMI patients undergoing pPCI.
Expert Opinion:
Antithrombotic therapy for STEMI patients undergoing pPCI should take into account the variability of thrombotic and bleeding risk in the short and long term. Patients with STEMI profit from the administration of early onset antiplatelet agents and anticoagulation to achieve sufficient and predictable antithrombotic effect at the time of pPCI. Thereafter, antithrombotic therapies should be tailored to individual risk of recurrence over the long term, to avoid excess bleeding, while ensuring adequate secondary ischemic prevention.
More Related Videos
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Coronary Artery Disease V: Interprofessional Care

